𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Glia: Initiators and progressors of pathology in Parkinson's disease

✍ Scribed by Glenda M. Halliday; Claire H. Stevens


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
732 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Background:

Glia are traditionally known as support cells for neurons, and their role in neurodegeneration has been largely considered secondary to neuronal dysfunction. We review newer concepts on glial function and assess glial changes in Parkinson's disease (PD) at the time of disease initiation when α‐synuclein is accumulating in brain tissue but there is limited neuronal loss, and also as the disease progresses and neuronal loss is evident.

Results:

Of the two main types of astrocytes, only protoplasmic astrocytes are involved in PD, where they become nonreactive and accumulate α‐synuclein. Experimental evidence has shown that astrocytic α‐synuclein deposition initiates the noncell autonomous killing of neurons through microglial signaling. As the disease progresses, more protoplasmic astrocytes are affected by the disease with an increasing microglial response. Although there is still controversy on the role microglia play in neurodegeneration, there is evidence that microglia are activated early in PD and possibly assist with the clearance of extracellular α‐synuclein at this time. Microglia transform to phagocytes and target neurons as the disease progresses but appear to become dysfunctional with increasing amounts of ingested debris. Only nonmyelinating oligodendroglial cells are affected in PD, and only late in the disease process.

Conclusions:

Glial cells are responsible for the progression of PD and play an important role in initiating the early tissue response. In particular, early dysfunction and α‐synuclein accumulation in astrocytes causes recruitment of phagocytic microglia that attack selected neurons in restricted brain regions causing the clinical symptoms of PD. © 2011 Movement Disorder Society


📜 SIMILAR VOLUMES


Milestones in Parkinson's disease—Clinic
✍ Glenda Halliday; Andrew Lees; Matthew Stern 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 350 KB 👁 1 views

## Abstract The identification of the widespread deposition of fibrillized α‐synuclein in Lewy bodies and Lewy neurites in the brains of patients with Parkinson's disease in 1997 has had a profound impact on how the disease is now conceptualized. The previous focus on the loss of the dopaminergic n

Mitochondrial pathology in Parkinson's d
✍ Russell H. Swerdlow; W. Davis Parker Jr. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

Although the ultimate origin and role of mitochondrial pathology in Parkinson's disease (PD) remains controversial, accumulating data suggest that mitochondrial dysfunction is genetic and plays an important role in neurodegeneration. PD mitochondria display abnormal electron transport chain activity

Prevalence of pathological gambling in p
✍ Maurizio Avanzi; Mario Baratti; Silvia Cabrini; Elena Uber; Gianni Brighetti; Fl 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

## Abstract Pathological gambling (PG) is a psychiatric disorder characterized by loss of control of gambling, which has repercussions on family, personal, and professional life. Several recent studies have reported the relationship between PG and the treatment of Parkinson's disease (PD), but no p

Cognitive dysfunctions and pathological
✍ Gabriella Santangelo; Carmine Vitale; Luigi Trojano; Francesca Verde; Dario Gros 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

## Abstract The purpose of this study was to investigate the neuropsychological correlates of pathological gambling (PG) in Parkinson's disease (PD). Fifteen patients with PD affected by PG (identified based on DSM‐IV criteria; PD+PG) without clinically evident dementia were compared with 15 nondem